Key result
Double therapy reduces major bleeding versus triple therapy after PCI in AF, but increases ischemic events.
Why the study?
Does double antithrombotic therapy reduce bleeding compared to triple antithrombotic therapy in patients with atrial fibrillation following percutaneous coronary intervention?
Does double antithrombotic therapy reduce bleeding compared to triple antithrombotic therapy in patients with atrial fibrillation following percutaneous coronary intervention?
In patients with atrial fibrillation undergoing PCI, double antithrombotic therapy with a NOAC reduces bleeding risk but increases the risk of stent-related ischemic events compared to triple therapy.
Answers are grounded in this paper and cite their sources.
Supports double therapy to reduce bleeding in AF-PCI patients; confirms the ischemic trade-off across trials.
Double antithrombotic therapy, particularly if consisting of a NOAC instead of VKA and a P2Y12 inhibitor, is associated with a reduction of bleeding, including major and intracranial haemorrhages. This benefit is however counterbalanced by a higher risk of cardiac-mainly stent-related-but not cerebrovascular ischaemic occurrences.
No takes yet. Share an insight, caveat, or question.
Gargiulo et al. (2019) studied this question. Double antithrombotic therapy with a NOAC and P2Y12 inhibitor reduced major and intracranial bleeding compared to triple therapy after PCI in AF, but increased stent-related cardiac ischemic events.
Synapse has enriched 10 related papers. Consider them for comparative context: